Teva Pharmaceutical Industries SUITS YOU announced its fourth quarter results on Wednesday, February 9, 2022 at 07:00.
Here’s what investors need to know about the announcement.
Check this out: Executives buy about $64 million from 3 stocks
Teva Pharmaceutical Indus beat estimated earnings by 5.48%, recording EPS of $0.77 versus an estimate of $0.73.
Revenue increased by $354.00 million compared to the same period last year.
Past Earnings Performance
Last quarter, the company missed EPS by $0.06, followed by a 2.24% decline in share price the next day.
Here is an overview of past performance of Teva Pharmaceutical Indus:
|Trimester||Q3 2021||Q2 2021||Q1 2021||Q4 2020|
|Actual turnover||3.89B||3.91B||3.98 billion||4.45B|
To keep track of all upcoming earnings announcements, click to use the Benzinga Earnings Calendar.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
If you don’t use this trading strategy, you are leaving money on the table…
If you look blindly and trade stocks like 99% of traders do, you are missing out on HUGE potential returns. Even new traders who started following this options trading strategy immediately started seeing returns that they wouldn’t have otherwise. With even two trades per month with this strategy, you will start to see the difference in your trading account. Stop wasting time “guessing” and “getting lucky”. Click here to see if you qualify for Benzinga options!
For today only, we’re offering our Benzinga Options Starter newsletter for just $7. This includes two highly sought-after trades per month by lead trader, Nic Chahine. For the same cost of a cup of coffee, less than the cost of a Netflix subscription, and less than the average order at McDonalds, you’ll receive top-tier education and winning business alerts to maximize your portfolio returns. This also includes a 14 day full money back guarantee if you cancel. There is absolutely no risk! Click here now to get started!